Research graph
References from Antibody desolvation with sodium chloride and acetonitrile generates bioactive protein nanoparticles. Local targets link to admitted publications; unresolved targets remain external evidence.
The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules
2022 · External reference
A potential approach for decreasing the burst effect of protein from PLGA microspheres
10.1002/jps.10414 · 2003 · External reference
Therapeutic application of peptides and proteins: parenteral forever?
10.1016/j.tibtech.2009.07.009 · 2009 · External reference
Toxicity as a result of immunostimulation by biologics
10.1517/17425255.3.2.209 · 2007 · External reference
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
10.1056/nejmoa1807315 · 2018 · External reference
Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer
10.1016/j.msec.2019.01.066 · 2019 · External reference
Cancer nanomedicine for combination cancer immunotherapy
10.1038/s41578-019-0108-1 · 2019 · External reference
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
10.1038/s41571-019-0308-z · 2020 · External reference
Delivery technologies for cancer immunotherapy
10.1038/s41573-018-0006-z · 2019 · External reference
Subcutaneous administration of monoclonal antibodies in oncology
10.1055/s-0034-1368173 · 2014 · External reference
Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles
10.2147/ijn.s152742 · 2018 · External reference
A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
10.1038/s41598-017-03959-4 · 2017 · External reference
Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration
10.1097/iae.0b013e3181a2f42a · 2009 · External reference
Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: Preliminary in vitro studies
10.1088/0957-4484/26/25/255102 · 2015 · External reference
The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments
10.1016/j.ejps.2013.07.014 · 2013 · External reference
Development of biodegradable nanocarriers loaded with a monoclonal antibody
10.3390/ijms16023990 · 2015 · External reference
Unintended Immunological Consequences of Biologic Therapy
10.1007/s11882-016-0624-7 · 2016 · External reference
The safety and side effects of monoclonal antibodies
10.1038/nrd3003 · 2010 · External reference
Commercial challenges of protein drug delivery
10.1517/17425247.2.1.29 · 2005 · External reference
Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation
10.1016/j.jconrel.2019.05.003 · 2019 · External reference
Effect of Needle Type and Injection Technique on Pain Level and Vitreal Reflux in Intravitreal Injection
10.1089/jop.2010.0082 · 2011 · External reference
ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20
10.1080/10717544.2018.1551442 · 2019 · External reference
Subcutaneous Administration: Evolution, Challenges, and the Role of Hyaluronidase
10.1188/21.cjon.663-671 · 2021 · External reference
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
10.1007/s12325-017-0610-z · 2017 · External reference
Nanoparticles for the delivery of therapeutic antibodies: Dogma or promising strategy?
10.1080/17425247.2017.1273345 · 2017 · External reference
Protein-fatty acid complex for enhanced loading and stability within biodegradable nanoparticles
10.1002/1520-6017(200102)90:2<194::aid-jps10>3.0.co;2-q · 2001 · External reference
Protein encapsulation via polypeptide complex coacervation
10.1021/mz500529v · 2014 · External reference
Improved enzyme activity and stability in polymer microspheres by encapsulation of protein nanospheres
10.1208/s12249-012-9794-3 · 2012 · External reference
Protein-based nanoparticles as drug delivery systems
10.3390/pharmaceutics12070604 · 2020 · External reference
Protein-based nanoparticles: From preparation to encapsulation of active molecules
10.1016/j.ijpharm.2017.01.067 · 2017 · External reference
Albumin-based nanoparticles as potential controlled release drug delivery systems
10.1016/j.jconrel.2011.07.031 · 2012 · External reference
Recent advances in protein-based nanoparticles and their applications in the delivery of bioactive compounds
10.1080/10942912.2023.2261662 · 2023 · External reference
Desolvation process and surface characterisation of protein nanoparticles
10.1016/s0378-5173(99)00370-1 · 2000 · External reference
Albumin nanoparticles with predictable size by desolvation procedure
10.3109/02652048.2011.635218 · 2012 · External reference
Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation
10.1016/j.ijpharm.2007.06.028 · 2008 · External reference
Optimization of the preparation process for human serum albumin (HSA) nanoparticles
10.1016/s0378-5173(03)00134-0 · 2003 · External reference
Robust size control of bovine serum albumin (BSA) nanoparticles by intermittent addition of a desolvating agent and the particle formation mechanism
10.1016/j.foodchem.2013.04.059 · 2013 · External reference
Investigation and modeling effective parameters influencing the size of BSA protein nanoparticles as colloidal carrier
10.1016/j.colsurfa.2012.07.022 · 2012 · External reference
Protein-based nanoparticle preparation via nanoprecipitation method
10.3390/ma11030394 · 2018 · External reference
The effect of different desolvating agents on BSA nanoparticle properties and encapsulation of curcumin
10.1007/s11051-014-2565-1 · 2014 · External reference
Preparation, Characteristics, and Advantages of Plant Protein-Based Bioactive Molecule Delivery Systems
10.3390/foods11111562 · 2022 · External reference
Egg white protein-based delivery system for bioactive substances: a review
2022 · External reference
Protein and Peptide-Based Nanotechnology for Enhancing Stability, Bioactivity, and Delivery of Anthocyanins
10.1002/adhm.202300473 · 2023 · External reference
Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres
10.1016/j.ejpb.2008.03.006 · 2008 · External reference
Two-step nanoprecipitation for the production of protein-loaded PLGA nanospheres
10.1016/j.rinphs.2012.11.001 · 2012 · External reference
Optimization of Protein Precipitation for High-Loading Drug Delivery Systems for Immunotherapeutics
10.3390/iecp2020-08683 · 2020 · External reference
Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodies
2017 · External reference
Comparing dose-response or kinetic curves with GraphPad Prism
1998 · External reference
The Control of Protein Stability and Association by Weak Interactions with Water: How Do Solvents Affect These Processes
10.1146/annurev.bb.22.060193.000435 · 1993 · External reference
Forces controlling protein interactions: theory and experiment
10.1016/s0927-7765(99)00027-2 · 1999 · External reference
Unresolved reference
2015 · External reference
Static dielectric constants of acetonitrile/water mixtures at different temperatures and debye-hückel A and a0B parameters for activity coefficients
10.1021/je700055p · 2007 · External reference
Maximizing recovery of water-soluble proteins through acetone precipitation
10.1016/j.aca.2013.08.005 · 2013 · External reference
Rapid and Quantitative Protein Precipitation for Proteome Analysis by Mass Spectrometry
10.1021/acs.jproteome.9b00867 · 2020 · External reference
Mass spectrometry profiling of low molecular weight proteins and peptides isolated by acetone precipitation
10.1016/j.aca.2020.08.057 · 2020 · External reference
Salt-mediated organic solvent precipitation for enhanced recovery of peptides generated by pepsin digestion
10.3390/proteomes9040044 · 2021 · External reference
Liquid high concentration IgG1 antibody formulations by precipitation
10.1002/jps.21526 · 2009 · External reference
Ethanol precipitation for purification of recombinant antibodies
10.1016/j.jbiotec.2014.07.436 · 2014 · External reference
Protein folding at emulsion oil/water interfaces
10.1016/j.cocis.2013.03.002 · 2013 · External reference
Encapsulation of Biologically Active Proteins in a Multiple Emulsion
10.1271/bbb.59.492 · 1995 · External reference
Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems
10.1016/j.addr.2023.114904 · 2023 · External reference
Lysozyme in water-acetonitrile mixtures: Preferential solvation at the inner edge of excess hydration
10.1063/1.4984116 · 2017 · External reference
Postproduction Handling and Administration of Protein Pharmaceuticals and Potential Instability Issues
10.1016/j.xphs.2018.04.005 · 2018 · External reference
Spray-Dried Monoclonal Antibody Suspension for High-Concentration and Low-Viscosity Subcutaneous Injection
10.1021/acs.molpharmaceut.2c00039 · 2022 · External reference
Intra-articular delivery of full-length antibodies through the use of an in situ forming depot
10.1016/j.jconrel.2021.12.010 · 2022 · External reference
Anti-PSMA/CD3 bispecific antibody delivery and antitumor activity using a polymeric depot formulation
10.1158/1535-7163.mct-17-1138 · 2018 · External reference
In-vitro, ex-vivo, and in-vivo evaluation of buprenorphine HCl release from an in situ forming gel of PLGA-PEG-PLGA using N-methyl-2-pyrrolidone as solvent
10.1016/j.msec.2018.11.058 · 2019 · External reference
